Document is current
Any future updates will be listed below
-
Authors
Helleux, Alexandra https://orcid.org/0000-0002-3499-6227
Davidson, Guillaume https://orcid.org/0000-0001-9272-3924
Lallement, Antonin
Hourani, Fatima Al
Haller, Alexandre
Michel, Isabelle
Fadloun, Anas
Thibault-Carpentier, Christelle https://orcid.org/0000-0003-1562-1451
Su, Xiaoping
Lindner, Véronique
Tricard, Thibault
Lang, Hervé
Tannir, Nizar M
Davidson, Irwin https://orcid.org/0000-0001-5533-1171
Malouf, Gabriel G https://orcid.org/0000-0003-3527-0417
-
Funding
Funding for this research was provided by:
Institut National Du Cancer (PRTK 2020-046)
Fondation ARC pour la Recherche sur le Cancer (Equipe labelisée)
Merck & Co. | MSD France | MSDAVENIR
- License Information
-
More Information
Article History
Received: 2 August 2024
Revised: 27 February 2025
Accepted: 4 March 2025
First Online: 27 March 2025
Disclosure and competing interests statement
: GGM reported consulting fees from BMS, MSD, IPSEN, and Eisai as well as research grants from MSD AVENIR.
